MGMarco Gipponi

Marco Gipponi

*This is an algorithmically generated author record based on publicly available information.

Marco Gipponi has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients

    by Marco Gipponi, Chiara Bassetti, Giuseppe Canavese, Alessandra Catturich, Carmine Di Somma, Carlo Vecchio, Guido Nicolò, Federico Schenone, Daniela Tomei, Ferdinando Cafiero

    Background and Objectives: Literature review suggests that the sentinel lymph node (sN) represents a reliable predictor of axillary lymph node status in breast cancer patients; however, some important issues, such as the optimisation of the technique for the intraoperative identification of the sN, the role of intraoperative frozen section examination of the sN, and the clinical implications of sN metastasis as regards the surgical management of the axilla, still require further confirmation. The authors aimed (1) to assess the feasibility of sN identification with a combined approach (vital blue dye lymphatic mapping and radioguided surgery, RGS) and the specific contribution of either techniques to the detection of the sN, (2) to determine the accuracy and usefulness of intraoperative frozen section examination of the sN in order to perform a one‐stage surgical procedure, and (3) to define how the sN might modulate the therapeutic planning in different stages of disease.Materials and Methods: From October 1997 to June 2001, 334 patients with early‐stage (T1–2 N0 M0) invasive mammary carcinoma underwent sN biopsy; the average age of patients was 61.5 years (range, 39–75 years). In a subset of 153 patients, both vital blue dye (Patent Blue‐V) lymphatic mapping and RGS were used to identify the sN, and the relative contribution of each of the two techniques was assessed.Results: In the whole group, the sN was identified in 326 of 334 patients (97.6%), and 105 of 326 patients (37.3%) had positive axillary lymph nodes (pN+). In 9 of 105 pN+ patients, the definitive histologic examination of the sN did not show metastases but these were detected in non‐sN, thus giving an 8.6% false‐negative rate, a negative predictive value of 94.5% (156/165), and an accuracy of 96.5% (252/261). As regards the specific contribution of the two different techniques used in the identification of the sN, the detection rate was 73.8% (113/153) with Patent Blue‐V alone, 94.1% (144/153) with RGS alone, and 98.7% (151/153) with Patent Blue‐V combined with RGS (P < 0.001). Noteworthy, whenever the sN was identified, the prediction of axillary lymph node status was remarkably similar (93–95% sensitivity; 100% specificity; 95–97% negative predictive value, and 97–98% accuracy) whichever of the three procedures was adopted (Patent Blue‐V alone, RGS alone, or combined Patent Blue‐V and RGS). Intraoperative frozen section examination was performed in 261 patients, who had at least one sN identified, out of 267 patients who underwent complete axillary dissection; 170 patients had histologically negative sN (i.o. sN−) and 91 patients histologically positive sN (i.o. sN+). All 91 i.o. sN+ were confirmed by definitive histology, whereas in 14 of 170 i.o. sN− patients (8.2%) metastases were detected at definitive histology. As regards the correlation between the size of sN metastasis, the primary tumour size, and the status of non‐sN in the axilla, micrometastases were detected at final histology in 23 patients and macrometastases in 82 patients. When only micrometastases were detected, the sN was the exclusive site of nodal metastasis in 20 of 23 patients (86.9%) while in 3 patients with tumour size larger than 10 mm micrometastases were detected also in non‐sN. Macrometastases were never detected in pT1a breast cancer patients; the sN was the exclusive site of these metastases in 30 patients (36.6%), while in 52 patients (63.4%) there were metastases both in sN and non‐sN.Conclusions: Sentinel lymphadenectomy can better be accomplished when both procedures (lymphatic mapping with vital blue dye and RGS) are used, because of the significantly higher sN detection rate, although the prediction of axillary lymph node status remains remarkably similar whichever method is used. The intraoperative frozen section examination proved to be rather accurate in predicting the actual pathologic status of the sN, with a negative predictive value of 91.8%; in 35% of patients it allowed sN biopsy and axillary dissection to be performed in a one‐stage surgical procedure. Finally, specific clinical and histopathologic features of the primary tumour and sN might be used to tailor the loco‐regional and systemic treatment in different clinical settings, such as in ductal carcinoma in‐situ (DCIS), early‐stage invasive breast cancer, and patients with large breast cancer undergoing neo‐adjuvant CT for breast‐saving surgery as well as elderly patients with operable breast cancer. J. Surg. Oncol. 2004;85:102–111.


  • New fields of application of the sentinel lymph node biopsy in the pathologic staging of solid neoplasms: Review of literature and surgical perspectives

    by Marco Gipponi, Nicola Solari, Franco C. Di Somma, Sergio Bertoglio, Ferdinando Cafiero

    Sentinel lymph node (sN) biopsy has gained special attention among surgical and medical oncologists as it represents an accepted technique for detecting occult nodal disease in regional lymph nodes of patients with melanoma and breast cancer. The histopathologic examination of the sN may well predict regional lymph node status in order to define the most suitable loco‐regional and systemic treatment. Recently, this technique has also been applied to other solid tumor types such as gynecologic and urologic malignancies, squamous head and neck cancer, thyroid cancer, non‐small‐cell lung cancer, Merkel cell carcinoma, and gastric cancer. The aim of this literature review is to define the rationale of sN biopsy in these tumor sites, the most effective procedure for sN detection, and the accuracy of the sN in predicting regional nodal status, as well as the surgical perspectives of sN biopsy application. J. Surg. Oncol. 2004;85:171–179.


  • Sentinel lymph node biopsy in patients with Stage I/II melanoma: Clinical experience and literature review

    by Marco Gipponi, Carmine Di Somma, Alberto Peressini, Nicola Solari, Sara Gliori, Guido Nicolo, Federico Schenone, Paola Queirolo, Mario Roberto Sertoli, Ferdinando Cafiero

    Background The sentinel lymph node (sN) represents one of the most powerful predictors of the outcome of patients with Stages I and II cutaneous melanoma, and may be relevant for the therapeutic planning of early‐stage melanoma patients. Since adopting the technique of lymphatic mapping with vital blue dye (Patent Blue‐V) in July 1993, we have periodically up‐dated the methodology and revised our results in order to define the contribution of radio‐guided surgery (RGS) to the detection of the sN as well as the role of intraoperative frozen section examination of the sN. Materials and Methods Between July 1993 and December 1997, 180 patients with clinically node‐negative primary cutaneous melanoma (Stages I–II) underwent sN biopsy followed by “selective lymph node dissection” (SLND) whenever sN metastasis was detected. Presently, complete data are available in 165 patients who were divided into two consecutive subsets of 39 and 126 patients, based on the technique for the identification of the sN: Patent Blue‐V only or Patent Blue‐V associated to RGS. Moreover, in this second subset of patients intraoperative frozen section findings were compared with definitive pathologic examination. Results As regards the first subset of 39 patients (17 males and 22 females; mean age 51.3 years), the sN was identified in 35 patients (89.7%); 8 patients (22.8%) were found to have metastatic melanoma cells in their sN, and they all underwent SLND of the affected basin. As regards the second set of 126 patients (54 males and 72 females; mean age 53.5 years), the sN was detected in every case by means of the combined technique (Patent Blue‐V and RGS): in 4 of 126 patients (3.2%), the sN was detected by means of RGS only whereas in no patient was the sN detected by Patent Blue‐V only. Frozen section examination was performed in 123 of 126 patients who had sN detection by Patent Blue‐V and RGS, and the intraoperative examination had a sensitivity of 66.6% (22 of 33), specificity of 100% (90 of 90), negative predictive value of 89.1% (90 of 101), and accuracy of 91% (112 of 123). The benefit of frozen section examination in avoiding a two‐stage procedure was 17.9% (22 of 123 patients). In patients with thicker lesions (pT3–pT4), the sensitivity and the benefit of intraoperative examination were 76% (19 of 25) and 32% (19 of 59 patients), respectively. Conclusions Sentinel node lymphadenectomy can be better accomplished when both procedures (lymphatic mapping with Patent Blue‐V and RGS) are used because the two methods look quite complementary. In fact, the use of the radiocolloid mapping allows to detect a hot spot in the regional basin prior to making the skin incision in order to perform a minimal invasive access, and it may also more accurately differentiate the true sN from a secondary echelon node (non‐sN). The use of frozen section examination should be restricted to patients with pT3–pT4 primary melanoma, due to the higher sensitivity and benefit in terms of avoiding a two‐stage operative procedure. J. Surg. Oncol. 2004;85:133–140.


  • Sentinel lymph node biopsy in melanoma patients: the medical oncologist's perspective

    by Paola Queirolo, Paola Taveggia, Marco Gipponi, Mario Roberto Sertoli

    With the advent of sentinel node (sN) biopsy in melanoma patients, elective lymph node dissection (ELND) can be considered an exceeded procedure. Regardless of the possible therapeutic benefits, sN biopsy efficiently predicts prognosis avoiding the morbidity rate of ELND. The importance of the sN is underlined by multivariate analyses, which show that the sN status represents the most important prognostic factor influencing disease-free and distant disease-free survival in patients with stage I and II melanoma. Moreover, sN biopsy provides a minimally invasive method for identifying those patients with subclinical nodal metastasis who actually have stage III disease, with a very high risk of occult distant metastases and who may benefit by adjuvant therapy.


  • Randomised clinical trial of adjuvant postoperative RT vs. sequential postoperative RT plus 5‐FU and levamisole in patients with stage II–III resectable rectal cancer: A final report

    by Ferdinando Cafiero, Marco Gipponi, Rita Lionetto, the P.A.R. Cooperative Study Group

    Background and Objectives: A randomised clinical trial was performed in patients undergoing radical surgery for rectal cancer to compare the efficacy and toxicity of adjuvant postoperative radiation therapy (RT) to sequential RT and chemotherapy (CT) with 5‐fluorouracil (5‐FU) plus levamisole (LEV). The primary end point was overall survival (OS); secondary end points were disease‐free survival (DFS), the rate of loco‐regional recurrence, and treatment‐related toxicity; the final results of this trial are reported.Methods: Patients in arm I underwent RT (50 Gy) in daily fractions of 2 Gy, 5 days/week for 5 weeks. Patients in arm II began with 5‐FU (450 mg/sqm/day intravenous (i.v.) bolus, days 1–5) plus LEV (150 mg/day orally, days 1–3); postoperative RT was delivered during week 2 at the same dosage and schedule as in arm I. The other five cycles of CT (5‐FU every 28 days and LEV every 15 days for the length of 5‐FU administration) continued after the end of RT if clinical and hemato‐biochemical parameters were in the normal range.Results: From May 1992 to December 1998, 218 patients were enrolled into the randomised clinical trial (144 men, 74 women; age range: 28–75, median 64 years). The median follow‐up time was 58.1 months (range: 1–3,271 days). No significant difference was observed between the two arms of treatment as regards OS and DFS (P = 0.18 and P = 0.66, respectively). Cox regression analysis for OS confirmed what was observed by univariate analysis for all variables except age. Older age (>60 years) and pathologic lymph‐node involvement defined the subgroups with the worst prognosis. Cox regression analysis for DFS confirmed what was observed by univariate analysis for all variables: the only independent variable in predicting DFS was pathologic lymph‐node involvement.Conclusions: Our findings suggest no difference in OS, loco‐regional and distant site progressions of postoperative RT alone compared to sequential postoperative RT and CT; notably, this latter regimen was associated with higher toxicity which seriously impaired the patient's compliance to CT. The low loco‐regional recurrence rate (9.2%) observed in our patients undergoing postoperative RT alone compared to similarly treated patients in previously performed clinical trials (20–25%) underline the role of radical surgery (mesorectal excision) coupled with a complete postoperative RT regimen. On the other hand, the similar efficacy of these two adjuvant modalities of treatment might be conditioned by both the low compliance (59%) to the CT regimen as well as the sequential, instead of concurrent, schedule of administration of RT and CT, which may have decreased further the expected efficacy of the combined regimen. J. Surg. Oncol. 2003;83:140–146


    • 1 June 2002
      • Vol. 43  (6) , 811-27

    Radioguided sentinel lymph node biopsy in malignant cutaneous melanoma.

    by Giuliano Mariani, Marco Gipponi, Luciano Moresco, Giuseppe Villa, Mirco Bartolomei, Giovanni Mazzarol, Maria Claudia Bagnara, Antonella Romanini, Ferdinando Cafiero, Giovanni Paganelli, et al.

    The procedure of sentinel lymph node biopsy in patients with malignant cutaneous melanoma has evolved from the notion that the tumor drains in a logical way through the lymphatic system, from the first to subsequent levels. As a consequence, the first lymph node encountered (the sentinel node) will most likely be the first affected by metastasis; therefore, a negative sentinel node makes it highly unlikely that other nodes in the same lymphatic basin are affected. Although the long-term therapeutic benefit of the sentinel lymph node biopsy per se has not yet been ascertained, this procedure distinguishes patients without nodal metastases, who can avoid nodal basin dissection with its associated risk of lymphedema, from those with metastatic involvement, who may benefit from additional therapy. Sentinel lymph node biopsy would represent a significant advantage as a minimally invasive procedure, considering that an average of only 20% of melanoma patients with a Breslow thickness between 1.5 and 4 mm harbor metastasis in their sentinel node and are therefore candidates for elective lymph node dissection. Furthermore, histologic sampling errors (amounting to approximately 12% of lymph nodes in the conventional routine) can be reduced if one assesses a single (sentinel) node extensively rather than assessing the standard few histologic sections in a high number of lymph nodes per patient. The cells from which cutaneous melanomas originate are located between the dermis and the epidermis, a zone that drains to the inner lymphatic network in the reticular dermis and, in turn, to larger collecting lymphatics in the subcutis. Therefore, the optimal route for interstitial administration of radiocolloids for lymphoscintigraphy and subsequent radioguided sentinel lymph node biopsy is intradermal or subdermal injection. (99m)Tc-Labeled colloids in various size ranges are equally adequate for radioguided sentinel lymph node biopsy in patients with cutaneous melanoma, depending on local experience and availability. For melanomas along the midline of the head, neck, and trunk, particular consideration should be given to ambiguous lymphatic drainage, which frequently requires interstitial administration virtually all around the tumor or surgical scar from prior excision of the melanoma. Lymphoscintigraphy is an essential part of radioguided sentinel lymph node biopsy because images are used to direct the surgeon to the sites of the nodes. The sentinel lymph node should have a significantly higher count than that of the background (at least 10:1 intraoperatively). After removal of the sentinel node, the surgical bed must be reexamined to ensure that all radioactive sites are identified and removed for analysis. Virtually the entire sentinel lymph node should be processed for histopathology, including both conventional hematoxylin-eosin staining and immune staining with antibodies to the S-100 and HMB-45 antigens. The success rate of radioguidance in localizing the sentinel lymph node in melanoma patients is approximately 98% in institutions that perform a high number of procedures and approaches 99% when combined with the vital blue-dye technique. Growing evidence of the high correlation between a sentinel lymph node biopsy negative for cancer and a negative status for the lymphatic basin-evidence, therefore, of the high prognostic value of sentinel node biopsy-has led to the procedure's being included in the most recent version of the TNM staging system and starting to become the standard of care for patients with cutaneous melanoma.


  • Radioimmunoguided surgery with different Iodine‐125 radiolabeled monoclonal antibodies in recurrent colorectal cancer

    by Pierluigi Percivale, Sergio Bertoglio, Paolo Meszaros, Federico Schenone, Marco Gipponi, Luciano Moresco, Maurizio Cosso, Fausto Badellino